89 related articles for article (PubMed ID: 15610849)
1. High-affinity small molecule inhibitors of T cell costimulation: compounds for immunotherapy.
Huxley P; Sutton DH; Debnam P; Matthews IR; Brewer JE; Rose J; Trickett M; Williams DD; Andersen TB; Classon BJ
Chem Biol; 2004 Dec; 11(12):1651-8. PubMed ID: 15610849
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
3. CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A.
Mukherjee S; Ahmed A; Nandi D
J Leukoc Biol; 2005 Jul; 78(1):144-57. PubMed ID: 15788440
[TBL] [Abstract][Full Text] [Related]
4. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
5. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
6. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
7. CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma.
Chen YQ; Shi HZ
Allergy; 2006 Jan; 61(1):15-26. PubMed ID: 16364152
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
[TBL] [Abstract][Full Text] [Related]
9. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.
Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M
Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799
[TBL] [Abstract][Full Text] [Related]
10. The B7 family and cancer therapy: costimulation and coinhibition.
Zang X; Allison JP
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5271-9. PubMed ID: 17875755
[TBL] [Abstract][Full Text] [Related]
11. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
12. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus.
Wong CK; Lit LC; Tam LS; Li EK; Lam CW
Rheumatology (Oxford); 2005 Aug; 44(8):989-94. PubMed ID: 15870153
[TBL] [Abstract][Full Text] [Related]
13. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
15. Feline B7.1 and B7.2 proteins produced from swinepox virus vectors are natively processed and biologically active: potential for use as nonchemical adjuvants.
Winslow BJ; Kalabat DY; Brown SM; Cochran MD; Collisson EW
Vet Microbiol; 2005 Nov; 111(1-2):1-13. PubMed ID: 16181751
[TBL] [Abstract][Full Text] [Related]
16. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
17. B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties.
Bhatia S; Edidin M; Almo SC; Nathenson SG
Immunol Lett; 2006 Apr; 104(1-2):70-5. PubMed ID: 16413062
[TBL] [Abstract][Full Text] [Related]
18. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation.
Kakoulidou M; Giscombe R; Zhao X; Lefvert AK; Wang X
Scand J Immunol; 2007 Nov; 66(5):529-37. PubMed ID: 17953528
[TBL] [Abstract][Full Text] [Related]
19. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive activity of the immunophilin-binding drug Sanglifehrin A in human whole blood: potent inhibition of interleukin-6 produced by lymphocytes and monocytes.
Härtel C; Iblher P; Puzik A; Wortmeier K; Ebel B; Schultz C; Müller-Steinhardt M
Scand J Immunol; 2006 Jan; 63(1):26-34. PubMed ID: 16398698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
